Compare IONQ & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONQ | VTRS |
|---|---|---|
| Founded | 2015 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Wholesale Distributors | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 18.7B |
| IPO Year | 2020 | 2019 |
| Metric | IONQ | VTRS |
|---|---|---|
| Price | $42.90 | $16.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $66.69 | $13.50 |
| AVG Volume (30 Days) | ★ 18.5M | 9.7M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $1,235,000,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $84.91 | $4.41 |
| Revenue Next Year | $53.45 | $1.96 |
| P/E Ratio | ★ N/A | $327.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.89 | $9.43 |
| 52 Week High | $84.64 | $18.39 |
| Indicator | IONQ | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 42.47 |
| Support Level | $38.88 | $15.82 |
| Resistance Level | $54.53 | $16.54 |
| Average True Range (ATR) | 2.60 | 0.52 |
| MACD | 1.60 | -0.19 |
| Stochastic Oscillator | 87.08 | 12.83 |
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.